Damage-associated molecular patterns - Emerging targets for biologic therapy of childhood arthritides

Inflammation and Allergy - Drug Targets

Volumn 8, Issue 2, 2009, Pages 139-145

  Lukić, Ivan Krešimir ^a   Jelušić Dražić, Marija ^b   Kovačić, Nataša ^c   Grčević, Danka ^c  

^a Biosistemi doo   (Croatia)

^b KBC Zagreb   (Croatia)

^c UNIVERSITY OF ZAGREB   (Croatia)

Author keywords

HMGB 1; Juvenile idiopathic arthritis; RAGE; S100 proteins

Indexed keywords

ADVANCED GLYCATION END PRODUCT RECEPTOR; ALARMIN; ANALGESIC, ANTIINFLAMMATORY, ANTIRHEUMATIC AND ANTIGOUT AGENTS; CALGRANULIN A; CALGRANULIN B; ETHYLPYRUVATE; HEAT SHOCK PROTEIN; HIGH MOBILITY GROUP B PROTEIN; HIGH MOBILITY GROUP B PROTEIN 1; HYALURONIC ACID; INFLIXIMAB; INTERLEUKIN 1; INTERLEUKIN 6; NUCLEAR PROTEIN; PROTEIN S 100; PROTEIN S 100A12; PSORIASIN; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; URATE;

ACUTE PANCREATITIS; ADULT RESPIRATORY DISTRESS SYNDROME; ARTHRITIS; BIOLOGICAL THERAPY; CEREBROVASCULAR ACCIDENT; HEART MUSCLE ISCHEMIA; HUMAN; INFLAMMATORY DISEASE; JUVENILE RHEUMATOID ARTHRITIS; NONHUMAN; PATHOGENESIS; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN STRUCTURE; PROTEIN SYNTHESIS INHIBITION; PROTEIN TARGETING; REPERFUSION INJURY; REVIEW; SEPSIS; VAGUS NERVE STIMULATION;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ARTHRITIS, JUVENILE RHEUMATOID; ARTHRITIS, RHEUMATOID; BIOLOGICAL MARKERS; BIOLOGICAL THERAPY; GENE EXPRESSION PROFILING; GLUCOCORTICOIDS; HMGB1 PROTEIN; HUMANS; IMMUNITY, INNATE; MICE; PROGNOSIS; RECEPTORS, IMMUNOLOGIC; S100 PROTEINS;

EID: 70349485139     PISSN: 18715281     EISSN: None     Source Type: Journal    
DOI: 10.2174/187152809788462617     Document Type: Review

References (94)

1. Ravelli, A.; Martini, A. Juvenile idiopathic arthritis. Lancet, 2007, 369, 767-778.
2. Petty, R.E.; Cassidy, J.T. Juvenile idiopathic arthritides. In Textbook of pediatric rheumatology; Petty RE, Cassidy JT, Ed.; WB Saunders Company: Philadelphia, London, New York, St. Louis, Toronto, 2001, 4th Ed, pp. 214-321.
3. Petty, R.E.; Southwood, T.R.; Baum, J.; Bhettay, E.; Glass, D.N.; Manners, P.; Maldonado-Cocco, J.; Suarez-Almazor, M.; Orozco-Alcala, J.; Prieur, A.M. Revision of the proposed classification criteria for juvenile idiopathis arthritis: Durban, 1997. J. Rheumatol., 1998, 25, 1991-1994.
4. Manners, P.J.; Bower, C. Worldwide prevalence of juvenile arthritis: why does it vary so much? J. Rheumatol., 2002, 29(7), 1520-1530.
5. Wallace, C.A.; Huang, B.; Bandeira, M.; Ravelli, A.; Giannini, E.H. Patterns of clinical remission in select categories of juvenile idiopathic arthritis. Arthritis Rheum., 2005, 52, 3554-3562.
6. Schneider, R.; Passo, M.H. Juvenile rheumatoid arthritis. Rheum. Dis. Clin. N. Am., 2002, 28, 503-530.
7. Cassidy, J.T. Medical management of children with juvenile rheumatoid arthritis. Drugs, 1999, 58, 831-850.
8. Agle, L.M.A.; Rosenkranz, M.; Lehman, T.J.A. Novel therapies for the treatment of juvenile rheumatoid arthritis (juvenile idiopathic arthritis). Expert Opin. Investig. Drugs, 2003, 12, 19-28.
9. Haines, K.A. Juvenile idiopathic arthritis: therapies in the 21st century. Bull. NYU Hosp. Jt. Dis., 2007, 65, 205-211.
10. Frosch, M.; Roth, J. New insights in systemic juvenile idiopathic arthritis. Rheumatology (Oxford), 2008, 47, 121-125.
11. Ravelli, A. Toward an understanding of the long-term outcome of juvenile idiopathic arthritis. Clin. Exp. Rheumatol., 2004, 22, 271-275.
12. Gartlehner, G.; Hansen, R.A.; Jonas, B.L.; Thieda, P.; Lohr, K.N. Biologics for the treatment of juvenile idiopathic arthritis: a systematic review and critical analysis of the evidence. Clin. Rheumatol., 2008, 27, 67-76.
13. Jelušić, M.; Lukić, I.K.; Batinić, D. Biologic agents targeting interleukin-18. Drug News Perspect., 2007, 20, 485-494.
14. Jelučić, M.; Lukić, I.K.; Tambić-Bukovac, L.; Dubravčić, K.; Malčić, I.; Rudan, I.; Batinić, D. Interleukin-18 as a mediator of systemic juvenile idiopathic arthritis. Clin. Rheumatol., 2007, 26, 1332-1334.
15. De Jager, W.; Hoppenreijs, E.P.; Wulffraat, N.M.; Wedderburn, L.R.; Kuis, W.; Prakken, B.J. Blood and synovial fluid cytokine signatures in patients with juvenile idiopathic arthritis: a cross-sectional study. Ann. Rheum. Dis., 2007, 66, 589-598.
16. Maeno, N.; Takei, S.; Nomura, Y.; Imanaka, H.; Hokonohara, M.; Miyata, K. Highly elevated serum levels of interleukin-18 in systemic juvenile idiopathic arthritis but not in other juvenile idiopathic arthritis subtypes or in Kawasaki disease: comment on the article by Kawashima et al. Arthritis Rheum., 2002, 46, 2539-2541.
17. Foell, D.; Wittkowski, H.; Roth, J. Mechanisms of disease: a 'DAMP' view of inflammatory arthritis. Nat. Clin. Pract. Rheumatol., 2007, 3, 382-90.
18. Oppenheim, J.J.; Yang, D. Alarmins: chemotactic activators of immune response. Curr. Opin. Immunol., 2005, 17, 359-65.
19. Goodwin, G.H.; Sanders, C.; Johns, E.W. A new group of chromatin-associated proteins with a high content of acidic and basic amino acids. Eur. J. Biochem., 1973, 38, 14-19.
20. Yamada, S.; Maruyama, I. HMGB-1: a novel inflammatory cytokine. Clin. Chim. Acta, 2007, 375, 36-42.
21. Klune, J.R.; Dhupar, R.; Cardinal, J.; Billiar, T.R.; Tsung, A. HMGB1: endogenous danger signaling. Mol. Med., 2008, 14, 476-84.
22. Wang, H.; Bloom, O.; Zhang, M.; Vishnubhakat, J.M.; Ombrellino, M.; Che, J.; Frazier, A.; Yang, H.; Ivanova, S.; Borovikova, L.; Manogue, K.R.; Faist, E.; Abraham, E.; Andersson, J.: Andersson, U.; Molina, P.E.; Abumrad, N.N.; Sama, A.; Tracey, K.J. HMG-1 as a late mediator of endotoxin lethality in mice. Science, 1999, 285, 248-251.
23. Scaffidi, P.; Misteli, T.; Bianchi, M.E. Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature, 2002, 418, 191-195.
24. Abraham, E.; Arcaroli, J.; Carmody, A.; Wang, H.; Tracey, K.J. HMG-1 as a mediator of acute lung inflammation. J Immunol., 2000, 165, 2960-2964.
25. Hori, O.; Brett, J.; Slattery, T.; Cao, R.; Zhang, J.; Chen, J.X.; Nagashima, M.; Lundh, E.R.; Vijay, S.; Nitecki, D. The receptor for the advanced glycation end products (RAGE) is a cellular binding site for amphoterin. Mediation of neurite outgrowth and coexpression of RAGE and amphoterin in the developing nervous system. J. Biol. Chem., 1995, 270, 25752-25761.
26. Park, J.S.; Svetkauskaite, D.; He, Q.; Kim, J.Y.; Strassheim, D.; Ishizaka, A.; Abraham, E. Involvement of toll-like receptors 2 and 4 in cellular activation by high mobility group box 1 protein. J. Biol. Chem., 2004, 279, 7370-7377.
27. Tian, J.; Avalos, A.M.; Mao, S.Y.; Chen, B.; Senthil, K.; Wu, H.; Parroche, P.; Drabic. S.; Golenbock, D.; Sirois, C.; Hua, J.; An, L.L.; Audoly, L.; La Rosa, G.; Bierhaus, A.; Naworth, P.; Marshak-Rothstein, A.; Crow, M.K.; Fitzgerald, K.A.; Latz, E.; Kiener, P.A.; Coyle, A.J. Toll-like receptor 9-dependent activation by DNA-containing immune complexes is mediated by HMGB1 and RAGE. Nat. Immunol., 2007, 8, 487-496.
28. Andersson, U.; Wang, H.; Palmblad, K.; Aveberger, A.C.; Bloom, O.; Erlandsson-Harris, H.; Janson, A.; Kokkola, R.; Zhang, M.; Yang, H.; Tracey, K.J. High mobility group 1 protein (HMG-1) stimulates proinflammatory cytokine synthesis in human monocytes. J. Exp. Med., 2000, 192, 565-70.
29. Li, J.; Wang, H.; Mason, J.M.; Levine, J.; Yu, M.; Ulloa, L.; Czura, C.J.; Tracey, K.J.; Yang, H. Recombinant HMGB1 with cytokine-stimulating activity. J. Immunol. Methods, 2004, 289, 211-23.
30. Ulloa, L.; Messmer, D. High-mobility group box 1 (HMGB1) protein: friend and foe. Cytokine Growth Factor Rev., 2006, 17, 189-201.
31. Rouhiainen, A.; Kuja-Panula, J.; Wilkman, E.; Pakkanen, J.; Stenfors, J.; Tuominen, R.K.; Lepäntalo, M.; Carpén, O.; Parkkinen, J.; Rauvala, H. Regulation of monocyte migration by amphoterin (HMGB1). Regulation of monocyte migration by amphoterin. Blood, 2004, 104, 1174-1182.
32. Orlova, V.V.; Choi, E.Y.; Xie, C.; Chavakis, E.; Bierhaus, A.; Ihanus, E.; Ballantyne, C.M.; Gahmberg, C.G.; Bianchi, M.E.; Nawroth, P.P.; Chavakis, T. A novel pathway of HMGB1-mediated inflammatory cell recruitment that requires Mac-1-integrin. EMBO J., 2007, 26, 1129-39.
33. Rendon-Mitchell, B.; Ochani, M.; Li, J.; Han, J.; Wang, H.; Yang, H.; Susarla, S.; Czura, C.; Mitchell, R.A.; Chen, G.; Sama, A.E.; Tracey, K.J.; Wang, H. IFN-gamma induces high mobility group box 1 protein release partly through a TNF-dependent mechanism. J. Immunol., 2003, 170, 3890-3897.
34. Telusma, G.; Datta, S.; Mihajlov, I.; Ma, W.; Li, J.; Yang, H.; Newman, W.;, Messmer, B.T.; Minev, B.; Schmidt-Wolf, I.G.; Tracey, K.J.; Chiorazzi, N.; Messmer, D. Dendritic cell activating peptides induce distinct cytokine profiles. Int. Immunol., 2006, 18, 1563-1573.
35. Messmer, D.; Yang, H.; Telusma, G.; Knoll, F.; Li, J.; Messmer, B.; Tracey, K.J.; Chiorazzi, N. High mobility group box protein 1: an endogenous signal for dendritic cell maturation and Th1 polarisation. J. Immunol., 2004, 173, 307-313.
36. Adib-Conquy, M.; Cavaillon, J.M. Stress molecules in sepsis and systemic inflammatory response syndrome. FEBS Lett., 2007, 581, 3723-3733.
37. Moore, B.W. A soluble protein characteristic of the nervous system. Biochem. Biophys. Res. Commun., 1965, 19, 739-744.
38. Foell, D.; Wittkowski, H.; Vogl, T.; Roth, J. S100 proteins expressed in phagocytes: a novel group of damage-associated molecular pattern molecules. J. Leukoc. Biol., 2007, 8, 28-37.
39. Rammes, A.; Roth, J.; Goebeler, M.; Klempt, M.; Hartmann, M.; Sorg, C. Myeloid-related protein (MRP) 8 and MRP14, calcium-binding proteins of the S100 family, are secreted by activated monocytes via a novel, tubulin-dependent pathway. J. Biol. Chem., 1997, 272, 9496-9502.
40. Hofmann, M.A.; Drury, S.; Fu, C.; Qu, W.; Taguchi, A.; Lu, Y.; Avila, C.; Kambham, N.; Bierhaus, A.; Nawroth, P.; Neurath, M.F.; Slattery, T.; Beach, D.; McClary, J.; Nagashima, M.; Morser, J.; Stern, D.; Schmidt, A.M. RAGE mediates a novel proinflammatory axis: a central cell surface receptor for S100/calgranulin polypeptides. Cell, 1999, 97, 889-901.
41. Viemann, D.; Strey, A.; Janning, A.; Jurk, K.; Klimmek, K.; Vogl, T.; Hirono, K.; Ichida, F.; Foell, D.; Kehrel, B.; Gerke, V.; Sorg, C.; Roth, J. Myeloid-related proteins 8 and 14 induce a specific inflammatory response in human microvascular endothelial cells. Blood, 2005, 105, 2955-2962.
42. Yan, W.X.; Armishaw, C.; Goyette, J.; Yang, Z.; Cai, H.; Alewood, P.; Geczy, C.L. Mast cell and monocyte recruitment by S100A12 and its hinge domain. J. Biol. Chem., 2008, 283, 13035-13043.
43. Yang, Z.; Yan, W.X.; Cai, H.; Tedla, N.; Armishaw, C.; Di Girolamo, N.; Wang, H.W.; Hampartzoumian, T.; Simpson, J.L.; Gibson, P.G.; Hunt, J.; Hart, P.; Hughes, J.M.; Perry, M.A.; Alewood, P.F.; Geczy, C.L. S100A12 provokes mast cell activation: a potential amplification pathway in asthma and innate immunity. J. Allergy Clin. Immunol., 2007, 119, 106-114.
44. Fuellen, G.; Foell, D.; Nacken, W.; Sorg, C.; Kerkhoff, C. Absence of S100A12 in mouse: implications for RAGE-S100A12 interaction. Trends Immunol., 2003, 24(12), 622-624.
45. Bianchi, M.E. DAMPs, PAMPs, and alarmins: all we need to know about danger. J. Leukoc. Biol., 2007, 81, 1-5.
46. Schmitt, E.; Gehrmann M.; Brunet, M.; Multhoff, G.; Garrido, C. Intracellular and extracellular functions of heat shock proteins: repercussions in cancer therapy. J. Leukoc. Biol., 2007, 81, 15-27.
47. Werman, A.; Werman-Venkert, R.; White, R.; Lee, J.K.; Werman, B.; Krelin, Y.; Voronov, E.; Dinarello, C.A.; Apte R.N. The precursor form of IL-1alpha is an intracrine proinflammatory activator of transcription. Proc. Natl. Acad. Sci. USA, 2004, 101, 2434-2439.
48. Lukić, I.K.; Humpert, P.M.; Nawroth, P.P.; Bierhaus, A. The RAGE pathway: activation and perpetuation in the pathogenesis of diabetic neuropathy. Ann. N. Y. Acad. Sci., 2008, 1126, 76-80.
49. Chavakis, T.; Bierhaus, A.; Nawroth, P.P. RAGE (receptor for advanced glycation end products): a central player in the inflammatory response. Microbes Infect., 2004, 6, 1219-1225.
50. Areschoug, T.; Gordon, S. Pattern recognition receptors and their role in innate immunity: focus on microbial protein ligands. Contrib. Microbiol., 2008, 15, 45-60.
51. Yan, S.F.; Barile, G.R.; D'Agati, V.; Du Yan, S.; Ramasamy, R.; Schmidt, A.M. The biology of RAGE and its ligands: uncovering mechanisms at the heart of diabetes and its complications. Curr. Diab. Rep., 2007, 7, 146-153.
52. Chavakis, T.; Bierhaus, A.; Al-Fakhri, N.; Schneider, D.; Witte, S.; Linn, T.; Nagashima, M.; Morser, J.; Arnold, B.; Preissner, K.T.; Nawroth, P.P. The pattern recognition receptor (RAGE) is a counter-receptor for leukocyte integrins: a novel pathway for inflammatory cell recruitment. J. Exp. Med., 2003, 198, 1507-1515.
53. Yan, S.D.; Chen, X.; Fu, J.; Chen, M.; Zhu, H.; Roher, A.; Slattery, T.; Zhao, L; Nagashima, M.; Morser, J.; Migheli, A.; Nawroth, P.; Stern, D.; Schmidt, A.M. RAGE and amyloid-beta peptide neurotoxicity in Alzheimer's disease. Nature, 1996, 382, 685-691.
54. Wolf, R.; Howard, O.M.; Dong, H.F., Voscopoulos, C.; Boeshans, K.; Winston, J.; Divi, R.; Gunsior, M.; Goldsmith, P.; Ahvazi, B.; Chavakis, T.; Oppenheim, J.J.; Yuspa, S.H. Chemotactic activity of S100A7 (psoriasin) is mediated by the receptor for advanced glycation end products and potentiates inflammation by highly homologous but functionally distinct S100A15. J. Immunol., 2008, 181, 1499-1506.
55. Bierhaus, A.; Stern, D.M.; Nawroth, P.P. RAGE in inflammation: a new therapeutic target? Curr. Opin. Investig. Drugs, 2006, 7, 985-991.
56. Raucci, A.; Cugusi, S.; Antonelli, A.; Barabino, S.M.; Monti, L.; Bierhaus, A.; Reiss, K.; Saftig, P.; Bianchi, M.E. A soluble form of the receptor for advanced glycation endproducts (RAGE) is produced by proteolitic cleavage of the membrane-bound form by the sheddase a disintegrin and and metalloprotease 10 (ADAM10). FASEB J., 2008, 22, 3716-3727.
57. Bierhaus, A.; Haslbeck, K.M.; Humpert, P.M.; Liliensiek, B.; Dehmer, T.; Morcos, M.; Sayed, A.A.; Andrassy, M.; Schiekofer, S.; Schneider, J.G.; Schulz, J.B.; Heuss, D.; Neundörfer, B.; Dierl, S.; Huber, J.; Tritschler, H.; Schmidt, A.M.; Schwaninger, M., Haering, H.U.; Schleicher, E.; Kasper, M.; Stern, D.M.; Arnold, B.; Nawroth, P.P. Loss of pain perception in diabetes is dependent on a receptor of the immunoglobulin superfamily. J. Clin. Invest., 2004, 114, 1741-1751.
58. Touré, F.; Zahm, J.M.; Garnotel, R.; Lambert, E.; Bonnet, N.; Schmidt, A.M.; Vitry, F.; Chanard, J.; Gillery, P.; Rieu, P. Receptor for advanced glycation end-products (RAGE) modulates neutrophil adhesion and migration of glycoxidated extracellular matrix. Biochem. J., 2008, 416, 255-261.
59. Manfredi, A.A.; Capobianco, A.; Esposito, A.; De Cobelli, F.; Canu, T.; Monno, A.; Raucci, A.; Sanvito, F.; Doglioni, C.; Nawroth, P.P.; Bierhaus, A.; Bianchi, M.E.; Rovere-Querini, P.; Del Maschio, A. Maturing dendritic cells depend on RAGE for in vivo homing to lymph nodes. J. Immunol., 2008, 180, 2270-2275.
60. Tian, J.; Avalos, A.M.; Mao, S.Y.; Chen, B.; Senthil, K.; Wu, H.; Parroche, P.; Drabic, S.; Golenbock, D.; Sirois, C.; Hua, J.; An, L.L.; Audoly, L.; La Rosa, G.; Bierhaus, A.; Naworth, P.; Marshak-Rothstein, A.; Crow, M.K.; Fitzgerald, K.A.; Latz, E.; Kiener, P.A.; Coyle, A.J. Toll-like receptor 9-dependent activation by DNA-containing immune complexes is mediated by HMGB1 and RAGE. Nat. Immunol., 2007, 8, 487-496.
61. Liliensiek, B.; Weigand, M.A.; Bierhaus, A.; Nicklas, W.; Kasper, M.; Hofer, S.; Plachky, J.; Gröne, H.J.; Kurschus, F.C.; Schmidt, A.M.; Yan, S.D.; Martin, E.; Schleicher, E.; Stern, D.M.; Hämmerling, G.G.; Nawroth, P.P.; Arnold, B. Receptor for advanced glycation end products (RAGE) regulates sepsis but not adaptive immune response. J. Clin. Invest., 2004, 113, 1641-1650.
62. Moser, B.; Desai, D.D.; Downie, M.P.; Chen, Y.; Yan, S.F.; Herold, K.; Schmidt, A.M.; Clynes, R. J. Immunol., 2007, 179, 8051.
63. Chen, Y.; Akirav, E.M.; Chen, W.; Henegariu, O.; Moser, B.; Desai, D.; Shen, J.M.; Webster, J.C.; Andrews, R.C.; Mjalli, A.M.; Rothlein, R.; Schmidt, A.M.; Clynes, R.; Herold, K.C. Receptors for advanced glycation end products expression on T cell contributes to antigen-specific cellular expansion in vivo. J. Immunol., 2008, 181, 4272-4278.
64. Taniguchi, N.; Kawahara, K.; Yone, K.; Hashiguchi, T.; Yamakuchi, M.; Goto, M.; Inoue, K.; Yamada, S.; Ijiri, K.; Matsunaga, S.; Nakajima, T.; Komiya, S.; Maruyama, I. High mobility group box chromosomal protein 1 plays a role in the pathogenesis of rheumatoid arthritis as a novel cytokine. Arthritis Rheum., 2003, 48, 971-981.
65. Goldstein, R.S.; Bruchfeld, A.; Yang, L.; Qureshi, A.R.; Gallowitsch-Puerta, M.; Patel, N.B.; Huston, B.J.; Chavan, S.; Rosas-Ballina, M.; Gregersen, P.K.; Czura, C.J.; Sloan, R.P.; Sama, A.E.; Tracey, K.J. Cholinergic anti-inflammatory pathway activity and High Mobility Group Box-1 (HMGB1) serum levels in patients with rheumatoid arthritis. Mol. Med., 2007, 13, 210-215.
66. Lotze, M.T.; Tracey, K.J. High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal. Nat. Rev. Immunol., 2005, 5, 331-342.
67. Bovin, L.F.; Rieneck, K.; Workman, C.; Nielsen, H.; Sorensen, S.F.; Skjødt, H.; Florescu, A.; Brunak. S.; Bendtzen, K. Blood cell gene expression profiling in rheumatoid arthritis. Discriminative genes and effect of rheumatoid factor. Immunol. Lett., 2004, 93, 217-226.
68. Sunahori, K.; Yamamura, M.; Yamana, J.; Takasugi, K.; Kawashima, M.; Yamamoto, H.; Chazin, W.J.; Nakatani, Y.; Yui, S.; Makino, H. The S100A8/ A9 heterodimer amplifies proinflammatory cytokine production by macrophages via activation of nuclear factor kappa B p38 mitogen-activated protein kinase in rheumatoid arthritis. Arthritis Res. Ther., 2006, 8, R69.
69. Foell, D.; Kane, D.; Bresnihan, B.; Vogl, T.; Nacken, W.; Sorg, C.; Fitzgerald, O.; Roth, J. Expression of the pro-inflammatory protein S100A12 (EN-RAGE) in rheumatoid and psoriatic arthritis. Rheumatology (Oxford), 2003, 42, 1383-1389.
70. de Seny, D.; Fillet, M.; Ribbens, C.; Marée, R.; Meuwis, M.A.; Lutteri, L.; Chapelle, J.P.; Wehenkel, L.; Louis, E.; Merville, M.P.; Malaise, M. Monomeric calgranulin measured by SELDI-TOF mass spectrometry and calprotectin measured by ELISA as biomarkers in arthritis. Clin. Chem., 2008, 54, 1066-1075.
71. Wittkowski, H.; Foell, D.; af Klint, E.; De Rycke, L.; De Keyser, F.; Frosch, M.; Ulfgren, A.K.; Roth, J. Effects of intra-articular corticosteroids and anti-TNF therapy on neutrophil activation in rheumatoid arthritis. Ann. Rheum. Dis., 2007, 66, 1020-1025.
72. Yang, Z.; Tao, T.; Raftery, M.J.; Youssef, P.; Di Girolamo, N.; Geczy, C.L. Proinflammatory properties of the human S100 protein S100A12. J. Leukoc. Biol., 2001, 69, 986-994.
73. Frosch, M.; Strey, A.; Vogl, T.; Wulffraat, N.M.; Kuis, W.; Sunderkoetter, C.; Harms, E.; Sorg, C.; Roth, J. Myeloid-related proteins 8 and 14 are specifically secreted during interactions of phagocytes and activated endothelium and are useful markers for monitoring disease activity in pauciarticular-onset juvenile rheumatoid arthritis. Arthritis Rheum.2000, 43, 628-637.
74. Drinda, S.; Franke, S.; Rüster, M.; Petrow, P.; Pullig, O.; Stein, G.; Hein, G. Identification of the receptor for advanced glycation end products in synovial tissue of patients with rheumatoid arthritis. Rheumatol. Int. 2005, 25, 411-413.
75. Sunahori, K.; Yamamura, M.; Yamana, J.; Takasugi, K.; Kawashima, M.; Makino, H. Increased expression of receptor for advanced glycation end products by synovial tissue macrophages in rheumatoid arthritis. Arthritis Rheum., 2006, 54, 97-104.
76. Hofmann, M.A.; Drury, S.; Hudson, B.I.; Gleason, M.R.; Qu, W.; Lu, Y.; Lalla, E.; Chitnis, S.; Monteiro, J.; Stickland, M.H.; Bucciarelli, L.G.; Moser, B.; Moxley, G.; Itescu, S.; Grant, P.J.; Gregersen, P.K.; Stern, D.M.; Schmidt, A.M. RAGE and arthritis: the G82S polymorphism amplifies the inflammatory response. Genes Immun., 2002, 3, 123-135.
77. Pullerits, R.; Bokarewa, M.; Dahlberg, L.; Tarkowski, A. Decreased levels of soluble receptor for advanced glycation end procucts in patients with rheumatoid arthritis indicating deficient inflammatory control. Arthritis Res. Ther., 2005, 7, R817-R824.
78. Pullerits, R.; Bokarewa, M.; Dahlberg, L.; Tarkowski, A. Synovial fluid expression of autoantibodies specific to RAGE relates to less erosive course of rheumatoid arthritis. Rheumatology (Oxford), 2007, 46, 1367-1371.
79. Rosenberg, A.M.; Cordeiro, D.M. Relationship between sex and antibodies to high mobility group proteins 1 and 2 in juvenile idiopathic arthritis. J. Rheumatol., 2000, 27, 2489-2493.
80. Frosch, M.; Vogl, T.; Seeliger, S.; Wulffraat, N.; Kuis, W.; Viemann, D.; Foell, D.; Sorg, C.; Sunderkötter, C.; Roth, J. Expression of myeloid-related proteins 8 and 14 in systemic-onset juvenile rheumatoid arthritis. Arthritis Rheum., 2003, 48, 2622-2626.
81. Foell, D.; Roth, J. Proinflammatory S100 proteins in arthritis and autoimmune disease. Arthritis Rheum., 2004, 50, 3762-3771.
82. Wulffraat, N.M.; Haas, P.J.; Frosch, M.; De Kleer, I.M.; Vogl, T.; Brinkman, D.M.; Quartier, P.; Roth, J.; Kuis, W. Myeloid related protein 8 and 14 secretion reflects phagocyte activation and correlates with disease activity in juvenile idiopathic arthritis treated with autologous stem cell transplantation. Ann. Rheum. Dis., 2003, 62, 236-41.
83. Wittkowski, H.; Hirono, K.; Ichida, F.; Vogl, T.; Ye, F.; Yanlin, X.; Saito, K.; Uese, K.; Miyawaki, T.; Viemann, D.; Roth, J.; Foell, D. Acute Kawasaki disease is associated with reverse regulation of soluble receptor for advanced glycation end products and its proinflammatory ligand S100A12. Arthritis Rheum., 2007, 56, 4174-4181.
84. Sundberg, E.; Grundtman, C.; Af Klingt, E.; Lindberg, J.; Ernestam, S.; Ulfgren, A.K.; Harris, H.E.; Andersson, U. Systemic TNF blockade does not modulate synovial expression of the proinflammatory mediator HMGB1 in rheumatoid arthritis patients - a prospective clinical study. Arthritis Res. Ther., 2008, 10, R33.
85. Abraham, E.; Anzueto, A.; Gutierrez, G.; Tessler, S.; San Pedro, G.; Wunderink, R.; Dal Nogare, A.; Nasraway, S.; Berman, S.; Cooney, R.; Levy, H.; Baughman, R.; Rumbak, M.; Light, R.B.; Poole, L.; Allred, R.; Constant, J.; Pennington, J.; Porter, S. Double blind randomized controlled trial of monoclonal antibody to tumor necrosis factor in treatment of septic shock. NORASEPT II Study Group. Lancet, 1998, 351, 929-933.
86. Abraham, E.; Reinhart, K.; Svoboda, P.; Seibert, A.; Olthoff, D.; Dal Nogare, A.; Postier, R.; Hempelmann, G.; Butler, T.; Martin, E.; Zwingelstein, C.; Percell, S.; Shu, V.; Leighton, A.; Creasey, A.A. Assessment of the safety of recombinant tissue factor pathway inhibitors in patients with severe sepsis: a multicenter, randomized, placebo-controlled, single-blind dose escalation study. Crit. Care Med., 2001, 29, 2081-2089.
87. Andrassy, M.; Volz, H.C.; Igwe, J.C.; Funke, B.; Eichberger, S.N.; Kaya, Z.; Buss, S.; Autschbach, F.; Pleger, S.T.; Lukić, I.K.; Bea, F.; Hardt, S.E.; Humpert, P.M.; Bianchi, M.E.; Mairbäurl, H.; Nawroth, P.P.; Remppis, A.; Katus, H.A.; Bierhaus, A. High-mobility group box-1 in ischaemia-reperfusion injury of the heart. Circulation, 2008, 117, 3216-3226.
88. Fink, M.P. Ethyl pyruvate: a novel anti-inflammatory agent. J. Intern. Med., 2007, 261, 349-362.
89. Hofer, S.; Eisenbach, C.; Lukić, I.K.; Schneider, L.; Bode, K.; Brueckmann, M.; Mautner, S.; Wente, M.N.; Encke, J.; Werner, J.; Dalpke, A.H.; Stremmel, W.; Nawroth, P.P.; Martin, E.; Krammer, P.H.; Bierhaus, A.; Weigand, M.A. Pharmacologic cholinesterase inhibition improves survival in experimental sepsis. Crit. Care Med., 2008, 36, 404-408.
90. Bopp, C.; Bierhaus, A.; Hofer, S.; Bouchon, A.; Nawroth, P.P.; Martin, E.; Weigand, M.A. Bench-to-bedside review: The inflammation-perpetuating pattern-recognition receptor RAGE as a therapeutic target in sepsis. Crit. Care, 2008, 12, 201.
91. Tracey. K.J. Physiology and immunology of the cholinergic anti-inflammatory pathway. J. Clin. Invest., 2007, 117, 289-296.
92. Hsu, K.; Passey, R.J.; Endoh, Y.; Rahimi, F.; Youssef, P.; Yen, T.; Geczy, C.L. Regulation of S100A8 by glucocorticoids. J. Immunol., 2005, 174, 2318-2326.
93. Lim, S.Y.; Raftery, M.; Cai, H.; Hsu, K.; Yan, W.X.; Hseih H.-L.; Watts, R.N.; Richardson, D.; Thomas, S.; Perry, M.; Geczy, C.L. S-Nitrosylated S100A8: Novel anti-inflammatory properties. J. Immunol., 2008, 181, 5627-5636.
94. Herold, K.; Moser, B.; Chen, Y.; Zeng, S.; Yan, S.F.; Ramasamy, R.; Emond, J.; Clynes, R.; Schmidt, A.M. Receptor for advanced glycation end products (RAGE) in dash to the rescue: inflammatory signals gone awry in the primal response to stress. J. Leukoc. Biol., 2007, 82, 204-212.